• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Apyx Medical Corporation

    10/31/24 5:44:01 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email
    SC 13G 1 sc13g14118002_10312024.htm SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    Apyx Medical Corporation

     (Name of Issuer)

    Common Stock, $0.001 par value

     (Title of Class of Securities)

    03837C106

     (CUSIP Number)

    October 31, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 03837C106

     

      1   NAME OF REPORTING PERSON  
             
            Strategos Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,794,920  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,794,920  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,794,920  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.18%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 03837C106

      1   NAME OF REPORTING PERSON  
             
            Strategos Master Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,320,361  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,320,361  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,320,361  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.81%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    3

    CUSIP No. 03837C106

     

      1   NAME OF REPORTING PERSON  
             
            Strategos Master Fund GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,320,361  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,320,361  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,320,361  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.81%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    4

    CUSIP No. 03837C106

     

      1   NAME OF REPORTING PERSON  
             
            Archon Capital Management LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Washington  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,115,281  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              3,115,281  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,115,281  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            8.99%  
      12   TYPE OF REPORTING PERSON  
             
            OO, IA  

      

    5

    CUSIP No. 03837C106

     

      1   NAME OF REPORTING PERSON  
             
            Constantinos Christofilis  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,115,281  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              3,115,281  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,115,281  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            8.99%  
      12   TYPE OF REPORTING PERSON  
             
            IN, HC  

      

    6

    CUSIP No. 03837C106

     

    Item 1(a).Name of Issuer:

     

    Apyx Medical Corporation, a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    5115 Ulmerton Road,

    Clearwater, Florida 33760

     

    Item 2(a).Name of Person Filing:
    Item 2(b).Address of Principal Business Office or, if None, Residence:
    Item 2(c).Citizenship:

     

    Strategos Fund, L.P. (“Strategos”)

    1100 19th Avenue E,

    Seattle, Washington 98112

    Citizenship: Delaware

     

    Strategos Master Fund, L.P. (“Strategos Master”)

    1100 19th Avenue E,

    Seattle, Washington 98112

    Citizenship: Cayman Islands

     

    Strategos Master Fund GP LLC (“Strategos GP”)

    1100 19th Avenue E,

    Seattle, Washington 98112

    Citizenship: Delaware

     

    Archon Capital Management LLC (“Archon”)

    1100 19th Avenue E,

    Seattle, Washington 98112

    Citizenship: Washington

     

    Constantinos Christofilis

    1100 19th Avenue E,

    Seattle, Washington 98112

    Citizenship: United States of America

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.001 par value per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    03837C106

     

    7

    CUSIP No. 03837C106

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    As of the close of business on October 31, 2024, (i) Strategos beneficially owned 1,794,920 Shares and (ii) Strategos Master beneficially owned 1,320,361 Shares.

     

    Strategos GP, as the general partner of Strategos Master, may be deemed to beneficially own the 1,320,361 Shares owned by Strategos Master.

     

    Archon, serving as the general partner and investment manager of Strategos and investment manager to Strategos Master, may be deemed to beneficially own the 1,794,920 Shares owned by Strategos and the 1,320,361 Shares owned by Strategos Master.

     

    Mr. Christofilis, as the Managing Member of Archon, may be deemed to beneficially own the 1,794,920 Shares owned by Strategos and the 1,320,361 Shares owned by Strategos Master.

     

    (b)Percent of class:

     

    The following percentages are based on 34,643,926 Shares outstanding, as of August 7, 2024, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

     

    8

    CUSIP No. 03837C106

    As of the close of business on October 31, 2024, (i) Strategos beneficially owned approximately 5.18% of the outstanding Shares, (ii) Strategos Master beneficially owned 3.81% of the outstanding Shares, (iii) Strategos GP may be deemed to beneficially own approximately 3.81% of the outstanding Shares and (iv) each of Archon and Mr. Christofilis may be deemed to beneficially own approximately 8.99% of the outstanding Shares.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    9

    CUSIP No. 03837C106

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: October 31, 2024

      STRATEGOS FUND, L.P.
       
      By: Archon Capital Management LLC, its General Partner
       
      By:

    /s/ Constantinos Christofilis

        Name: Constantinos Christofilis
        Title: Managing Member

     

     

      STRATEGOS MASTER FUND, L.P.
       
      By: Archon Capital Management LLC, its Investment Manager
       
      By:

    /s/ Constantinos Christofilis

        Name: Constantinos Christofilis
        Title: Managing Member

     

     

      STRATEGOS MASTER FUND GP LLC
       
      By: Archon Capital Management LLC, its Sole Member
       
      By:

    /s/ Constantinos Christofilis

        Name: Constantinos Christofilis
        Title: Managing Member

     

     

      ARCHON CAPITAL MANAGEMENT LLC
       
      By:

    /s/ Constantinos Christofilis

        Name: Constantinos Christofilis
        Title: Managing Member

     

     

     

    /s/ Constantinos Christofilis

      CONSTANTINOS CHRISTOFILIS

     

    10

     

    Get the next $APYX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    7/14/2023$8.00Overweight
    Stephens
    5/20/2022$12.00Buy
    Lake Street
    8/13/2021$12.00 → $14.00Market Outperform
    JMP Securities
    More analyst ratings

    $APYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr. V.P. of Operations Citronowicz Moshe

    4 - Apyx Medical Corp (0000719135) (Issuer)

    5/19/25 4:31:11 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Baylor-Henry Minnie

    4 - Apyx Medical Corp (0000719135) (Issuer)

    5/19/25 4:31:08 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Hill Matthew C

    4 - Apyx Medical Corp (0000719135) (Issuer)

    5/19/25 4:31:12 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Apyx Medical

    BTIG Research initiated coverage of Apyx Medical with a rating of Neutral

    10/17/24 7:28:31 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on Apyx Medical with a new price target

    Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00

    7/14/23 7:29:43 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Apyx Medical with a new price target

    Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00

    5/20/22 8:54:50 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company") today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx's Vice President, North American Sales as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $1.85, the closing price of Apyx Medical Corporation's common stock on August 4, 2025. The stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and the remain

    8/7/25 4:06:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Expands Global Sales Leadership with Strategic Hires to Support AYON Launch and Accelerated Growth

    CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation, an advanced energy technology company and manufacturer of Renuvion® and the newly launched AYON Body Contouring System™, today announced the strategic appointments of two accomplished sales executives to its leadership team. These additions support the Company's continued global expansion and the commercial launch of AYON, the industry's first all-in-one surgical body contouring system. John Featherstone has been named Vice President of North American Sales, bringing more than 20 years of experience in commercial leadership roles within the aesthetics and medical device industry. Most recently serving as Vice Pr

    8/7/25 4:05:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation Reports Second Quarter 2025 Financial Results

    Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial proceduresBased on pre-sales of AYON, the Company increased its total revenue guidance for FY2025 to a range of $50.0 million to $52.0 millionManagement to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Bod

    8/7/25 4:01:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

    4/A - Apyx Medical Corp (0000719135) (Issuer)

    3/3/25 4:05:12 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

    4 - Apyx Medical Corp (0000719135) (Issuer)

    8/13/24 6:56:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

    4 - Apyx Medical Corp (0000719135) (Issuer)

    12/14/23 9:00:19 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    SEC Filings

    View All

    Apyx Medical Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Apyx Medical Corp (0000719135) (Filer)

    8/13/25 4:00:32 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Apyx Medical Corporation

    10-Q - Apyx Medical Corp (0000719135) (Filer)

    8/7/25 4:08:08 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Apyx Medical Corp (0000719135) (Filer)

    8/7/25 4:04:22 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    11/28/23 8:30:00 AM ET
    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    3/1/22 4:05:00 PM ET
    $APYX
    $LNTH
    $PRTK
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations

    $APYX
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation Reports Second Quarter 2025 Financial Results

    Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial proceduresBased on pre-sales of AYON, the Company increased its total revenue guidance for FY2025 to a range of $50.0 million to $52.0 millionManagement to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Bod

    8/7/25 4:01:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

    CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international c

    7/24/25 4:05:00 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation Reports First Quarter 2025 Financial Results

    Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

    5/8/25 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Apyx Medical Corporation

    SC 13G - Apyx Medical Corp (0000719135) (Subject)

    10/31/24 5:44:01 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

    SC 13G/A - Apyx Medical Corp (0000719135) (Subject)

    10/15/24 9:18:53 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

    SC 13D/A - Apyx Medical Corp (0000719135) (Subject)

    5/9/24 7:45:22 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care